Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
10 November 2021 - 12:00AM
Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical
company developing STAR-0215 for the treatment of hereditary
angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief
Executive Officer, will present a corporate overview and provide
information on lead program STAR-0215 at the upcoming virtual
Jefferies London Healthcare Conference.
The presentation will be available to all conference attendees
on-demand beginning on Thursday, November 18, at 3:00am ET through
Friday, November 19, at 12:00pm ET.
A webcast of the event can be accessed from the Investors
section of www.astriatx.com and at the following link:
https://wsw.com/webcast/jeff201/atxs/1865664. An archived replay
will be available for 30 days following the event.
About Astria Therapeutics: Astria Therapeutics is a
biopharmaceutical company, and our mission is to bring
life-changing therapies to patients and families affected by rare
and niche allergic and immunological diseases. Our lead program,
STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein
in preclinical development for the treatment of hereditary
angioedema. Learn more about our company on our website,
www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx
and on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211109005334/en/
Astria:
Investor relations: Andrea Matthews
investors@astriatx.com
Media: Elizabeth Higgins media@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Apr 2023 to Apr 2024